Advertisement
Research Article Free access | 10.1172/JCI118480
National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850-3300, USA.
Find articles by Avis, I. in: JCI | PubMed | Google Scholar
National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850-3300, USA.
Find articles by Jett, M. in: JCI | PubMed | Google Scholar
National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850-3300, USA.
Find articles by Boyle, T. in: JCI | PubMed | Google Scholar
National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850-3300, USA.
Find articles by Vos, M. in: JCI | PubMed | Google Scholar
National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850-3300, USA.
Find articles by Moody, T. in: JCI | PubMed | Google Scholar
National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850-3300, USA.
Find articles by Treston, A. in: JCI | PubMed | Google Scholar
National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850-3300, USA.
Find articles by Martínez, A. in: JCI | PubMed | Google Scholar
National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850-3300, USA.
Find articles by Mulshine, J. in: JCI | PubMed | Google Scholar
Published February 1, 1996 - More info
Signal transduction pathways shared by different autocrine growth factors may provide an efficient approach to accomplish clinically significant control of lung cancer growth. In this study, we demonstrate that two autocrine growth factors activate 5-lipoxygenase action of the arachidonic acid metabolic pathway in lung cancer cell lines. Both growth factors increased the production of 5(S)-hydrooxyeicosa-6E,8Z,11Z,14Z-tetraeno ic acid (5-HETE), a major early 5-lipoxygenase metabolic product. Exogenously added 5-HETE stimulated lung cancer cell growth in vitro. Inhibition of 5-lipoxygenase metabolism by selective antagonists resulted in significant growth reduction for a number of lung cancer cell lines. Primary clinical specimens and lung cancer cell lines express the message for the 5-lipoxygenase enzymes responsible for the generation of active metabolites. In vivo evaluation demonstrated that interruption of 5-lipoxygenase signaling resulted in enhanced levels of programmed cell death. These findings demonstrate that 5-lipoxygenase activation is involved with growth factor-mediated growth stimulation for lung cancer cell lines. Pharmacological intervention with lipoxygenase inhibitors may be an important new clinical strategy to regulate growth factor-dependent stages of lung carcinogenesis.